{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:25:11Z","timestamp":1794936311223,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007313","name":"UT | University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016796","name":"Adaptive Biotechnologies","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016796","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01373-y","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:53:56Z","timestamp":1761051236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Macaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-8485","authenticated-orcid":false,"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Kugler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Garris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"1373_CR1","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.","journal-title":"JAMA Oncol"},{"key":"1373_CR2","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","volume":"9","author":"NJ Short","year":"2025","unstructured":"Short NJ, Aldoss I, DeAngelo DJ, Konopleva M, Leonard J, Logan AC, et al. Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv. 2025;9:1442\u201351.","journal-title":"Blood Adv"},{"key":"1373_CR3","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","volume":"6","author":"NJ Short","year":"2022","unstructured":"Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022;6:4006\u201314.","journal-title":"Blood Adv"},{"key":"1373_CR4","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1182\/bloodadvances.2021006727","volume":"6","author":"M Kotrov\u00e1","year":"2022","unstructured":"Kotrov\u00e1 M, Koopmann J, Trautmann H, Alakel N, Beck J, Nachtkamp K, et al. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods. Blood Adv. 2022;6:3006\u201310.","journal-title":"Blood Adv"},{"key":"1373_CR5","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/ajh.26949","volume":"98","author":"NJ Short","year":"2023","unstructured":"Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, et al. Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023;98:1196\u2013203.","journal-title":"Am J Hematol"},{"key":"1373_CR6","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","volume":"133","author":"W Stock","year":"2019","unstructured":"Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133:1548\u201359.","journal-title":"Blood"},{"key":"1373_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/ajh.25671","volume":"95","author":"M Yilmaz","year":"2020","unstructured":"Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, et al. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020;95:144\u201350.","journal-title":"Am J Hematol"},{"key":"1373_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K, Patel K, O\u2019Brien SM, Cortes JE, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. Blood. 2016;128:504\u20137.","journal-title":"Blood"},{"key":"1373_CR9","unstructured":"NCCN Guidelines. NCCN. 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1410."},{"key":"1373_CR10","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/j.clml.2023.12.016","volume":"24","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, et al. Dose-dense mini-hyper-CVD, inotuzumab ozogamicin and blinatumomab achieves rapid MRD-negativity in philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2024;24:e168\u201373.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1373_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ajh.27576","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Short NJ, Jain N, Haddad FG, Kadia T, Yilmaz M, et al. Hyper-CVAD and sequential blinatumomab without and with inotuzumab in young adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. Am J Hematol. 2025;100:402\u20137.","journal-title":"Am J Hematol"},{"key":"1373_CR12","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, et al. Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL. J Clin Oncol. 2024;42:4246\u201351.","journal-title":"J Clin Oncol"},{"key":"1373_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","volume":"3","author":"MA Pulsipher","year":"2022","unstructured":"Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S, et al. Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov. 2022;3:66\u201381.","journal-title":"Blood Cancer Discov"},{"key":"1373_CR14","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","volume":"7","author":"EC Liang","year":"2023","unstructured":"Liang EC, Dekker SE, Sabile JMG, Torelli S, Zhang A, Miller K, et al. Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation. Blood Adv. 2023;7:3395\u2013402.","journal-title":"Blood Adv"},{"key":"1373_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1182\/blood-2024-207557","volume":"144","author":"M Liedtke","year":"2024","unstructured":"Liedtke M, Sun Z, Litzow MR, Mattison RJ, Paietta E, Roberts KG, et al. Assessment of outcomes of allogeneic stem cell transplantation by treatment arm in newly diagnosed measurable residual disease negative patients with B-lineage acute lymphoblastic leukemia randomized to conventional chemotherapy +\/- blinatumomab in the ECOG-ACRIN E1910 phase III national clinical trials network trial. Blood. 2024;144:779.","journal-title":"Blood"},{"key":"1373_CR16","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","volume":"125","author":"N Dh\u00e9din","year":"2015","unstructured":"Dh\u00e9din N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125:2486\u201396.","journal-title":"Blood"},{"key":"1373_CR17","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","volume":"107","author":"M Br\u00fcggemann","year":"2006","unstructured":"Br\u00fcggemann M, Raff T, Flohr T, G\u00f6kbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116\u201323.","journal-title":"Blood"},{"key":"1373_CR18","first-page":"337","volume":"24","author":"N G\u00f6kbuget","year":"2019","unstructured":"G\u00f6kbuget N, Dombret H, Giebel S, Bruggemann M, Doubek M, Fo\u00e0 R, et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematol Amst Neth. 2019;24:337\u201348.","journal-title":"Hematol Amst Neth"},{"key":"1373_CR19","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1182\/blood-2024-201784","volume":"144","author":"I Aldoss","year":"2024","unstructured":"Aldoss I, Wang X, Zhang J, Guan M, Espinosa R, Agrawal V, et al. CD19-CAR T cells as definitive consolidation for older adults with B-cell acute lymphoblastic leukemia in first complete remission: a pilot study. Blood. 2024;144:966.","journal-title":"Blood"},{"key":"1373_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","volume":"36","author":"D O\u2019Connor","year":"2018","unstructured":"O\u2019Connor D, Enshaei A, Bartram J, Hancock J, Harrison CJ, Hough R, et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol J Am Soc Clin Oncol. 2018;36:34\u201343.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"1373_CR21","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood.2022016194","volume":"140","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, et al. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022;140:2101\u201312.","journal-title":"Blood"},{"key":"1373_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-term results of the dasatinib-blinatumomab protocol for adult philadelphia-positive ALL. J Clin Oncol J Am Soc Clin Oncol. 2024;42:881\u20135.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"1373_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","volume":"18","author":"NJ Short","year":"2025","unstructured":"Short NJ, Kantarjian H, Furudate K, Jain N, Ravandi F, Karrar O, et al. Molecular characterization and predictors of relapse in patients with Ph\u2009+\u2009ALL after frontline ponatinib and blinatumomab. J Hematol OncolJ Hematol Oncol. 2025;18:55.","journal-title":"J Hematol OncolJ Hematol Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01373-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01373-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01373-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:02:56Z","timestamp":1761094976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01373-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01373-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NJS, EJ, and NJ have received consulting fees and honoraria from Adaptive Biotechnologies. FGH received consulting fees from Amgen. The other authors report no relevant conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of MD Anderson Cancer Center (Reference No. PA18-0025) and was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived by the Institutional Review Board due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"169"}}